Literature DB >> 1569172

Cortisol inactivation overload: a mechanism of mineralocorticoid hypertension in the ectopic adrenocorticotropin syndrome.

S Ulick1, J Z Wang, J D Blumenfeld, T G Pickering.   

Abstract

The more severe mineralocorticoid manifestations in the ectopic ACTH syndrome compared to pituitary Cushing's disease have been attributed to hypersecretion of 11-deoxycorticosterone. Another difference between the two forms of ACTH-excess, however, is a more severe degree of hypercortisolism in the ectopic syndrome. Cortisol can become a potent mineralocorticoid if its peripheral metabolism is interfered with as occurs in the syndrome of apparent mineralocorticoid excess. This mechanism also occurs in an experimental model of the apparent mineralocorticoid excess syndrome induced by licorice derivatives. We have tested the hypothesis that cortisol is a major mineralocorticoid in the ectopic ACTH syndrome because of two factors, marked hypersecretion and incomplete peripheral metabolism of cortisol as a result of an overload of metabolizing enzymes. Two measures of the peripheral metabolism of cortisol were found to be markedly decreased in two patients with the ectopic ACTH syndrome. The cortisol turnover quotients were 17.2 and 19.6 (normal = 215 +/- 98) and the ring A reduction constants were 11.8 and 13.8 (normal = 101 +/- 23). These values were comparable to that found in the syndrome of apparent mineralocorticoid excess and consistent with the hypothesis that cortisol is a significant functioning mineralocorticoid in the ectopic ACTH syndrome.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1569172     DOI: 10.1210/jcem.74.5.1569172

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  19 in total

Review 1.  [Mineralocorticoid-induced hypertension].

Authors:  J Hensen; W Oelkers
Journal:  Med Klin (Munich)       Date:  1997-05-15

2.  Cushing's syndrome: all variants, detection, and treatment.

Authors:  Susmeeta T Sharma; Lynnette K Nieman
Journal:  Endocrinol Metab Clin North Am       Date:  2011-06       Impact factor: 4.741

Review 3.  The multifaceted mineralocorticoid receptor.

Authors:  Elise Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Compr Physiol       Date:  2014-07       Impact factor: 9.090

Review 4.  Central regulation of blood pressure by the mineralocorticoid receptor.

Authors:  Elise P Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Mol Cell Endocrinol       Date:  2011-06-01       Impact factor: 4.102

Review 5.  Mineralocorticoid receptors in the brain and cardiovascular regulation: minority rule?

Authors:  Elise P Gomez-Sanchez
Journal:  Trends Endocrinol Metab       Date:  2011-03-21       Impact factor: 12.015

6.  Role of ketoconazole treatment in urinary-free cortisol-to-cortisone and tetrahydrocortisol-to-tetrahydrocortisone ratios in nonectopic Cushing's syndrome.

Authors:  Pablo Stiefel; José S García-Morillo; Luis Jimenez; Encarnación Pamies; María Luisa Miranda; Joaquín Carneado; José Villar; Alfonso Leal-Cerro
Journal:  Endocrine       Date:  2002-08       Impact factor: 3.633

7.  [68-year-old female patient with dyspnea and hypokalemic hypertension].

Authors:  K Müssig; C Maser-Gluth; M Hartmann; M Wehrmann; M Horger; L Kanz; H-U Häring; S A Wudy
Journal:  Internist (Berl)       Date:  2007-10       Impact factor: 0.743

8.  Increased production of 11beta-hydroxysteroid dehydrogenase type 2 in the kidney microsomes of squirrel monkeys (Saimiri spp.).

Authors:  Patti W Sadosky; Jonathan G Scammell
Journal:  Comp Med       Date:  2008-04       Impact factor: 0.982

9.  Regulation of the 11 beta-hydroxysteroid dehydrogenase in the rat adrenal. Decrease enzymatic activity induced by ACTH.

Authors:  H Morita; E N Cozza; M Y Zhou; E P Gomez-Sanchez; D G Romero; C E Gomez-Sanchez
Journal:  Endocrine       Date:  1997-12       Impact factor: 3.633

Review 10.  Adrenocortical hypertension.

Authors:  Angelo Capricchione; Nathaniel Winer; James R Sowers
Journal:  Curr Hypertens Rep       Date:  2004-06       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.